New Haven-based online pharmacy Valisure’s CEO David Light spoke at the June 18 session of the WHIPgroup Tech Entrepreneur Meetup at our Stamford offices.
David and Valisure are in the news this week. They are the source for the troubling news that popular and effective acid-blocking drug Zantac and its generic form Radnitidine contain the known carcinogen NDMA.
In his talk at WHIPgroup, David led a fascinating discussion on the reasons impurities can get into the global drug supply and the tests, procedures and processes that Valisure uses to ensure their customers receive medications that are efficacious, at the right dosage, and free of harmful impurities.
If you would like to learn more about how Valisure found the NDMA in Zantac and other forms of Radnitidine, please click here.
If you would like to meet other leaders on the leading edge of technology, business and science, please join the WHIPgroup Meetup by clicking here. Our next session will be on October 15 and will explore the significant aquaculture business opportunity around Kelp farming in Long Island Sound.
Recently, WHIPGROUP engaged in an arbitration that included a five day hearing in the City. Here are some thoughts about why arbitration is different (not clearly better or worse) than litigation. Venue The AAA arbitral [Read More…]
WHIPGroup previously filed a Motion to Dismiss a patent infringement suit filed against its client TomTom in the Western District of Texas. Rather than opposing WHIPGroup’s motion to dismiss, Plaintiff MDSP Technologies LLC voluntarily dismissed [Read More…]
WHIPgroup succeeded in having anticipation and indefiniteness rejections overturned by the Patent Trial and Appeal Board (PTAB). The claimed invention relates to a sequencing station that manages both sequencing and restacking tasks. The Examiner had [Read More…]